Shares of Bajaj Healthcare Ltd rose 1.5% to a day’s high of Rs 506.45 on 6th October after the company announced that it had received approval from the Subject Expert Committee (SEC) (Neurology & Psychiatry) of the Central Drugs Standard Control Organisation (CDSCO) to conduct Phase III clinical trials of Suvorexant Tablets in India. The trials will cover tablet strengths of 5 mg, 10 mg, 15 mg, and 20 mg.

Bajaj Healthcare has become the first company in India to receive regulatory clearance for Suvorexant, a prescription drug for treating insomnia in adults. The drug works on the central nervous system to regulate the sleep-wake cycle, helping patients fall asleep and stay asleep.

The Phase III clinical trials will evaluate the drug’s safety, effectiveness, and tolerability across a wider patient base. This is the final stage before submitting to the regulatory authorities. If successful, the company will apply for marketing approval in select markets and move toward a commercial launch.

Managing Director Anil Jain said the SEC’s recommendation is an encouraging step and highlighted Bajaj Healthcare’s strong R&D and GMP-compliant manufacturing, adding that the company is committed to bringing high-quality CNS solutions to patients worldwide.

At 3:30 PM, the shares of Bajaj Healthcare ended 0.010% lower at Rs 484 on NSE.

Tired of missing hot stocks? Unicorn Signals provides powerful tools like stock scans and more help you make informed trading decisions. Download now and take control of your portfolio!